Ok, today it's the 17th, they were expected to start the trial in jan 2025 and they are not yet recruiting, but the trial is there!
Preclinical data highlight the potential of CLSP-1025, a first-in-class T-cell engager (TCE) targeting the p53 (R175H) mutation, prevalent in various solid tumors including prostate, colorectal, and lung cancers. This innovative therapy focuses on shared cancer neoantigens presented by HLA molecules, ensuring high specificity for cancer cells while sparing healthy tissues.
If successful, this would mark a milestone as the first TCE targeting a shared cancer neoantigen to enter clinical evaluation, offering a novel approach for cancers with significant unmet needs.
So, eyes open and fingers crossed!
OVM-200 Phase 1 clinical trial ( vaccine)